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Abstract 
Background: Immunohistochemistry (IHC) and fluorescent-in situ hybridization (FISH) are standard methods to 
assess human epidermal growth factor receptor 2 (HER2) status in breast cancer (BC) patients. Real-time quantita-
tive polymerase-chain-reaction (qRT-PCR) is able to detect HER2 overexpression. Here we compared FISH, IHC, 
quantitative PCR (qPCR), and qRT-PCR to determine the concordance rates and evaluate their relative roles in HER2 
determination.
Patients and methods: We determined HER2 status in 153 BC patients, using IHC, FISH, Q-PCR and qRT-PCR. In dis-
cordant cases, we directly measured HER2 protein levels using Western blotting.
Results: The overall agreement (OA) between FISH and Q-PCR was 94.1, with a k value of 0.87. Assuming FISH as the 
standard reference, Q-PCR showed an 86.1% sensitivity and a 99.0% specificity with a global accuracy of 91.6%. OA 
between FISH and qRT-PCR was 90.8% with a k value of 0.81. Of interest, the disagreement between FISH and qRT-PCR 
was mostly restricted to equivocal cases. HER2 protein analysis suggested that qRT-PCR correlates better than FISH 
with HER2 protein levels, particularly where FISH fails to provide conclusive results.
Significance: qRT-PCR may outperform FISH in identifying patients overexpressing HER2 protein. Q-PCR cannot be 
used for HER2 status assessment, due to its suboptimal level of agreement with FISH. Both FISH and Q-PCR may be 
less accurate than qRT-PCR as surrogates of HER2 protein determination.
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(http://creativecommons.org/licenses/by/4.0/), which permits unrestricted use, distribution, and reproduction in any medium, 
provided you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, 
and indicate if changes were made. The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/
publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated.
Background
Human epidermal growth factor receptor 2 (HER2) is a 
predictive biomarker for therapeutic decisions in breast 
cancer.
Because direct HER2 protein assessment is not con-
sistently reproducible in formalin-fixed tissues, a debate 
exists regarding the optimal surrogate tests for HER2 
determination.
The American Society of Clinical Oncology/College 
of American Pathologists (ASCO/CAP) recommends 
IHC as a standard procedure for HER2 assessment, 
combined, in equivocal cases, with additional testing by 
in situ hybridization (ISH) assay with fluorescent (FISH) 
or chromogenic (CISH) probes [1, 2].
Moreover, ISH-based assessment is advocated for poor 
prognosis IHC +1 cases to avoid misclassification of such 
cases [3–5].
Although the IHC/ISH approach consents to classify 
the vast majority of HER2 positive tumors, these tissue-
based tests are not devoid of interpretative issues and 
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Combining IHC and ISH still yields to results falling 
on the equivocal area that could incorrectly subtract true 
positive cases from an effective anti-HER2 therapy. Fur-
thermore, this analyses fail to identify a small but still 
clinically relevant proportion of patients that, although 
properly classified as non-HER2 amplified, overexpresses 
HER2 via non amplification-mediated mechanisms, and 
who may still benefit from treatment with trastuzumab 
[7–11].
Accordingly, there is room for improving current HER2 
analysis methods with the use of alternative approaches.
The use of PCR-based tests in place of conventional 
methods is not routinely accepted, mostly because sev-
eral studies failed to establish a consistently reproducible 
high level of agreement with “golden standard” tests [12].
Here we aimed to analyze HER2 RNA expression using 
quantitative real-time PCR (qRT-PCR), comparing the 
obtained results with PCR performed on DNA (Q-PCR) 
under rigorously controlled experimental conditions in 
153 tumor samples. Moreover, we compared discrepan-
cies between DNA and RNA measurement by Western 
blotting in a representative subset of cases. All samples 
underwent a systematic pre-test microscopy assessment 
to ensure sufficient tumor cellularity. Blinded independ-




The study population included 153 patients with invasive 
ductal or lobular breast cancer retrospectively selected 
according to locally determined HER2 IHC and FISH 
results. We analyzed the above mentioned number of 
cases based on the assumption that we would need at 
least 152 samples to reach a kappa value of 0.95 for agree-
ment between different methodologies, with 5% discord-
ant cases.
The initial routine pathological examination, includ-
ing HER2 IHC and FISH when necessary, was performed 
on formalin-fixed and paraffin-embedded (FFPE) tumor 
samples at the Pathology Unit of Genoa University.
We enriched this series in IHC HER2 positive (3+) 
patients to avoid the potential selection bias resulting 
from the high number of HER2-negative cases observed 
in routine practice. In fact, it has been demonstrated that 
the large prevalence of negative cases in not enriched 
series biases the comparison in favor of generating high 
concordances between assays [12].
In addition, we decided to include 22 cases (14% of 
the study population) classified as FISH equivocal, with 
the aim of a more statistically robust assessment of 
molecular tests performance in this small but clinically 
relevant subpopulation. To meet the selection criteria 
for inclusion in the present study, FISH equivocal cases 
required a confirmatory FISH re-counting of at least 60 
invasive tumor cells.
After retrospective selection, all cases were tested for 
FISH, gene copy number and gene expression by inde-
pendent, blinded operators. Molecular analyses were 
performed at the Department of Internal Medicine of 
Genoa University and FISH analysis was carried out at 
the Department of Biomedical Sciences and Human 
Oncology of Turin University.
Written informed consent for molecular analysis was 
obtained from all alive and traceable patients, in agree-
ment with the Italian Law and the Declaration of Hel-
sinki. Ethical approval of this retrospective study was 
granted by the IRCCS AOU San Martino-IST Research 
Ethics Committee (approval number P.R.01/13).
Tissue specimens
Twelve tumor sections were obtained from the each 
FFPE block. The first and twelfth section (slides) of 
each sample were hematoxylin and eosin-stained (H&E-
stained). These were examined by an experienced 
pathologist (P.B.) to determine the relative amount 
of tumor, benign epithelial and stromal cells, and to 
exclude the presence of in  situ carcinomatous cells. 
Tumor sections with ≥70% of tumor cells were directly 
analyzed. Samples with a lower than 70% cellularity 
were subjected to macro- or micro-dissection (Laser 
Capture Microdissection, Histogene-Arcturus, CA). 
Sections #2 to #4 of each specimen (5  μm thick) were 
used for FISH analysis, whereas sections five to eleven 
(8  μm thick) were used for DNA and RNA extraction. 
Glass slides were stored at −80 °C until the extraction of 
nucleic acids.
Immunohistochemistry and FISH analysis
For immunohistochemical HER2 determination, sections 
were incubated with the rabbit monoclonal primary anti-
body VENTANA anti-HER2/neu (4B5) (Ventana, Tuc-
son, AZ, USA). Evaluation of IHC stains was performed 
by an experienced pathologist (P.B.), and scored accord-
ing to the Manufacturer’s specifications [13]. FISH reac-
tion was performed with PathVysion HER2 DNA Probe 
Kit (Abbott Molecular) according to the Manufacturer’s 
instructions. Analysis of HER2/CEP17 signals was done 
on ten areas selected by an experienced pathologist 
(L.V.C. and C.B.) and automatically acquired and read 
by the Imager MetaSystem (Zeiss) (http://www.meta-
systems-international.com), properly equipped, through 
PathVysionV2 classifier (FDA approved). Automatic read-
ing of each case was verified with Isis software (Zeiss). 
Heterogeneous  cases3 were counted on the Isis images. 
Cases were FISH scored according to ASCO/CAP 2013 
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guidelines and BICE AIOM/SIAPEC 2014 consensus rec-
ommendations [14, 15].
Extraction of genomic DNA and total RNA
DNA was isolated using QIAamp DNA FFPE Tissue Kit 
(Qiagen GmbH, D-40724 Hilden) according to the Man-
ufacturer’s protocol, and was therefore diluted in 60  μL 
elution buffer (ATE).
RNA was isolated using Paradise™ Reagent System 
(Arcturus) after incubation with proteinase K for 16  h 
at 56  °C. A Dnase I treatment step was included. RNA 
was diluted in 50 μL elution buffer (EB), according to the 
Manufacturer’s protocol.
DNA and RNA quantities were measured using two 
different methods, NanoDrop Spectrophotometer (ND-
1000 Celbio, MI) and Qubit™ fluorimeter (Invitrogen, 
CA). Fluorimetric analysis was performed by Quant-iT 
dsDNA HS Assay Kit and Quant-iT™ Assay Kit (Invitro-
gen, CA) for, respectively, DNA and RNA.
Quantitative PCR analysis
Quantitative PCR (Q-PCR) analyses for genes encoding 
HER2 and control Amyloid beta A4 precursor protein 
(APP, chromosomal location 21q21.3) were performed 
in 96-well plates and were carried out using the 7900HT 
Fast Real-Time PCR System (Applied Biosystems™, Fos-
ter City, CA, USA).
The sequences of the oligonucleotide primers and 
probes used for Q-PCR were derived from Lehman et al. 
[16].
Q-PCR conditions were as follows: PCR reactions were 
performed in 96-well plates with 7900HT fast PCR sys-
tem (Applied Biosystems™—by Life Technologies™ Fos-
ter City, CA, USA). Reaction mixture for HER2, as well 
as APP reference gene, were set up in a 25 μL final vol-
ume containing up to 5 μL DNA (30 ng/μL), each 2.5 μL 
of the forward and reverse primers (final concentration: 
each 300  nM), 2.5  μL of the hybridization probes (final 
concentration 200  nM), and 12.5  μL of the Universal 
Master Mix (all reagents from Applied Biosystems™—by 
Life Technologies™ Foster City, CA, USA). The essays 
were started by denaturation for 2 min at 50 °C, 10 min 
at 95 °C and followed by 40 cycles of 95 °C for 15 s and 
60  °C for 1  min. The HER2 amplified breast cancer cell 
line SKBR3 served as internal positive control.
Quantitative real‑time RT‑PCR
To evaluate gene expression, the first-strand cDNA syn-
thesis was performed from variable amounts (between 50 
and 200 ng) of total RNA extracted with random hexam-
ers by using High Capacity cDNA Archive Kit (Applied 
Biosystems™, Foster City, CA) in a final volume of 50 μL, 
according to the Manufacturer’s protocol.
HER2 and reference gene were preamplified using 
12.5 μL of cDNA mixed with 25 μL of TaqMan PreAmp 
Master Mix and 12.5 μL of assay pool containing the 
mix of the two assays ID Hs00170433-ERBB2 and 
Hs99999902_m1-RPLP0 (Applied Biosystems™, Foster 
City, CA), 0.2X each. Preamplification allows for linear 
amplification of mRNA without significantly distorting 
relative mRNA levels [17].
The reaction was performed following the Manufac-
turer’s protocol with 14 cycles of amplification. The pre-
amplification product was diluted 1:5. The qRT-PCR 
reactions were run for 2 min at 50  °C, 10 min at 95  °C, 
followed by 40 cycles of 15 s at 95 °C and 1 min at 60 °C. 
All qRT-PCR reactions, for HER2 as well as RPLP0 gene, 
were performed on the ABI 7900 HT system, and were 
measured in triplicate to ensure methodological repro-
ducibility. This was considered adequate if within a maxi-
mum of 0.3 threshold PCR cycle (Ct) variation.
The qRT-PCR reactions were set up in 96-well plates, 
in a final volume of 20 μL containing up to 5 μL pream-
plified cDNA, 1  μL of TaqMan gene expression assay, 
4 μL of molecular water, and 10 μL of the Universal Mas-
ter Mix (all reagents from Applied Biosystems ™—by Life 
Technologies™ Foster City, CA, USA). Breast cancer cell 
line SKBR3, containing high levels of HER2, served as 
internal positive control.
Calculation of HER2 gene copy number and expression
In the real-time PCR-based quantitative analyses, ini-
tial DNA or RNA template concentration is correlated 
with the time at which the fluorescent signal crosses a 
threshold in the exponential phase of the polymerase 
chain reaction. Because this time is measured in terms of 
threshold PCR cycle (Ct), the initial template concentra-
tion can be derived from the Ct number. In each meas-
urement, the normalization of DNA or RNA load by a 
housekeeping gene is required: gene reference (APP) to 
normalize the DNA and an housekeeping gene (RPLP0) 
to normalize the RNA. Amplification status of HER2 
gene was determined on tumor DNA by Q-PCR. The 
APP gene was chosen as internal reference because its 
amplification efficiency was found to be similar to HER2 
gene (data not shown) and infrequent copy number vari-
ations have been reported in breast cancer for this gene 
[16]. Amplification analysis is based on the ratio between 
the gene dosage measured in the tumor tissue sample and 
the corresponding measure in the normal human DNA 
chosen as calibrator (Human Genomic DNA, Takara 
Bio Europe/Clontech™, Saint Germain-en-Laye, France). 
Because this is a quantitative relative measure, the calcu-
lation was made according to the following formula: fold 
induction =  2−[ΔΔCt], where ΔΔCt =  [Ct HER2 (tumor 
sample) − Ct APP (tumor sample)] − [Ct HER2 (normal 
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DNA)  −  Ct APP (normal DNA)]. Amplification was 
defined as a  2−[ΔΔCt] result above the cut-off value of 1.5, 
determined in DNA samples from peripheral leukocytes 
of 25 normal donors and by the optimal value (defined 
as the threshold with the maximum sum of sensitivity 
and specificity) in the receiver-operating-characteristic 
(ROC) curves comparing Q-PCR with FISH status for 
the 121 non-equivocal cases of the present dataset (see 
Fig. 1a).
We determined HER2 gene expression on tumor RNA 
by quantitative RT-PCR technique (qRT-PCR). For this 
test, RPLP0 was adopted as endogenous reference gene, 
because it is reported as invariant in breast tissue and in 
preliminary experiments its amplification efficiency was 
found to be similar to HER2 gene (internal data and Lyng 
et al. [18]).
Relative quantification of HER2 gene expression was 
performed according to the  2−ΔΔCt method. This algo-
rithm is used to calculate the change in expression of a 
gene of interest relative to a calibrator sample chosen to 
represent 1× expression of the gene of interest. In the 
present analysis normal breast tissue (Human Mammary 
Gland Poli A+RNA Clontech, Mountain View, CA, USA) 
was adopted as calibrator.
The calculation of HER2 gene relative expression was 
performed according to the following formula: fold 
induction =  2−[ΔΔCt], where ΔΔCt =  [Ct HER2 (tumor 
sample) − Ct RPLP0 (tumor sample)] − [Ct HER2 (nor-
mal breast sample) − Ct RPLP0 (normal breast sample)]. 
Similar to Q-PCR, we determined the best cut-off to dis-
criminate between HER2 positive and negative cases as a 
value = 1.1, by using the ROC curve method on the non-
equivocal samples (see Fig. 1b).
We have to highlight that, in light of the variability of 
RNA and, partially, DNA degradation observed in FFPE 
tissue samples, the results of gene expression and copy 
number analysis can not be assumed as absolute meas-
ures. As a consequence, we transformed the obtained 
values into categorical variables, to compare them with 
results obtained by other analytical methods used to 
determine HER2 status [19, 20].
Reconstitution in vitro experiments
To assess the dilution effect by not-HER2 amplified 
cells, tumor or not, on both Q-PCR and qRT-PCR 
methods, the levels of both HER2 copy number and 
expression were measured in serial dilutions of HER2 
positive mammary carcinoma cell line SKBR3 with 
MCF10A cells, an immortalized HER2 negative breast 
tissue-derived cell line. In brief, different percent-
age dilutions of SKBR3:MCF10A were mixed, ranging 
from 100 to 5%, then the whole cell population was 
lysed and nucleic acids extracted. Copy number and 
expression analyses were performed on cell pellets 
according with the same methods used for tumor tis-
sue sections, as described in the previous paragraphs. 
Results are reported as an average of three independent 
experiments.
Fig. 1 ROC curves for Q-PCR (a) and Q-RT-PCR (b) compared to FISH in non-equivocal cases. The blue and green squares represent the corrected 
partial areas under the curve (pAUC) for the graphic regions encompassing the 100–95% specificity and sensitivity areas, respectively. The value on 
the topleft corner of each panel indicates the optimal cutoff, with specificity and sensitivity in parentheses
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HER2 protein analysis (immunoblotting)
The FFPE tissue samples available for HER2 protein anal-
ysis were processed as follows. Four serial sections (about 
100  mm2 and 8  μm thick) for each sample were placed 
in collection tubes (QIAGEN GmbH, Hilden). Protein 
extraction was performed using Qproteome FFPE Tissue 
Kit (QIAGEN GmbH, Hilden), according to the Manu-
facturer’s specifications. After we proceeded with the 
separation (25 μg for each sample) by SDS-PAGE (4–12%, 
Life Technologies™ Foster City, CA, USA). Proteins were 
transferred onto PVDF membrane (Immobilon-P, Mil-
lipore S.p.A., Vimodrone, Italy) and were detected using 
primary antibody for HER2 and Gamma Tubulin (Cell 
Signaling Technology, Inc. Danvers, MA 01923) and sec-
ondary antibodies horseradish peroxidase–conjugated 
anti-mouse or anti-rabbit (Cell Signaling Technology, 
Inc. Danvers, MA 01923). Enhanced chemiluminescence 
(Thermo Scientific Pierce ECL Western Blotting Sub-
strate 3747 N Meridian Rd, Rockford, IL USA 61101) was 
detected by ChemiDoc (XRS+ System, Bio-Rad Labora-
tories Headquarters 1000 Alfred Nobel Drive Hercules, 
CA 94547).
HER2 protein quantity was calculated as HER2:tubulin 
optical density ratio assuming the ratio measured in 
MCF10 cell line as normal control.
Statistical analysis
We performed concordance analysis (overall, positive and 
negative agreement) and the relative confidence intervals 
(Clopper-Pearson exact method) according to estab-
lished definitions. The strength of agreement was evalu-
ated using the Cohen’s unweighted kappa test. When 
assuming FISH as gold standard was appropriate sensi-
tivity, specificity, positive and negative predictive values, 
likelihood ratios and accuracy, meant as the area under 
the ROC curve (AUC) according to the DeLong method, 
were calculated. The confidence intervals for likelihood 
ratios were obtained with the first method described in 
Using the first method described in Koopman, Biomet-
rics, Vol. 40, No. 2 (Jun., 1984), pp. 513–517. Power cal-
culations and statistical analyses were performed within 
the R environment for statistical computing, and the 
packages statmod, gdata, gmodels, PropCIs, pROC, and 
psych were used. All tests were two-tailed, and consid-
ered significant at a P value <0.05.
Results
Concordance between IHC and FISH
IHC and FISH testing results obtained in this study pop-
ulation are reported in Table 1. According to IHC score, 
47 out of the 153 cases we included were classified as 3+, 
49 as 2+, and 57 as either 1+ or 0. By FISH analysis, 51 
patients (45 out of 47 IHC 3+ cases, and 6 out of 49 2+ 
cases) were HER2 amplified, while 102 were not (80 neg-
ative and 22 equivocal).
IHC testing had a good degree of agreement with FISH, 
as classified by ASCO/CAP criteria 2013. The overall 
agreement (OA), calculated assuming IHC score 0, 1+ 
and 2+ as negative, and equivocal and negative cases 
together for FISH, was 92.2% (95% CI 86.7–95.9), average 
positive agreement (PA) was 88.5% (95% CI 80.7–93.9), 
and average negative agreement (NA) was 94.1% (95% CI 
89.9–96.9). These data show discordance between IHC 
and FISH (7.8%, 95% CI 4.1–13.3) as in line with current 
results obtained by reference laboratories, with values 
around 5% [21].
Dilution and amplification effects
Q-PCR and qRT-PCR give, respectively, the mean num-
ber of gene copies and the mean mRNA amount among 
all the cell populations present in any analyzed tumor tis-
sue section.
The results of our in vitro experiments show that both 
tests were able to detect the signal in a wide range of 
SKBR3 to MCF10A ratios, from 100:0 to 5:95 (Fig. 2). The 
observed detection threshold of 5% in these in vitro con-
ditions suggests that molecular tests have the ability to 
detect even very small fractions of positive cells among a 
whole cell population.
Overall, these results provide evidence against the 
hypothesis that the dilution effect could constitute a real 
bias in properly selected, microscopy assessed tumor 
specimens. Moreover, the absence of altered signal in the 
HER2-cell line and in normal breast tissue supports the 
conclusion that PCR methods do not detect HER2 signal 
when analyzed cell populations do not carry the molecu-
lar alteration.
Concordance between FISH and Q‑PCR
OA between FISH and Q-PCR, calculated considering 
FISH-equivocal cases as non-amplified, was 94.1% (95% 
CI 89.1–97.3%), PA was 91.6% (95% CI 84.6–96.1%), 
and NA was 95.5% (95% CI 91.6–97.9%). Agreement 
strength was very good with a k value of 0.87 (95% CI 
0.79–0.95).
Table 1 Concordance between IHC versus FISH
IHC immunohistochemistry, FISH fluorescence in situ hybridization
IHC testing FISH testing, N (%)
FISH positive FISH negative
0 0 (0) 44 (100)
1+ 0 (0) 13 (100)
2+ 6 (12.2) 43 (87.8)
3+ 45 (95.7) 2 (4.3)
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Assuming FISH as the reference standard, Q-PCR 
had a sensitivity  =  86.0% (95% CI 74.2–93.7%), speci-
ficity  =  99.0% (95% CI 94.3–99.9%), positive predic-
tive value (PV) =  98.0% (95% CI 89.3–99.9%), negative 
PV  =  92.2% (95% CI 85.3–96.6%), positive likelihood 
ratio = 82.5 (95% CI 11.7–581.5). Accuracy of Q-PCR in 
comparison, measured as the area under the ROC curve 
(AUC) with FISH was 91.6% (96% CI 85.4–97.9%).
Concordance between FISH and qRT‑PCR
FISH and qRT-PCR determine HER2 status at two dif-
ferent molecular levels (DNA and RNA). Hence, we 
only compared them by calculating agreement meas-
ures [22]. In our case series OA, calculated considering 
FISH-equivocal cases as non-amplified, was 90.8% (95% 
CI 85.1–94.9%), PA was 88.3% (95% CI 81.2–93.5%), and 
NA was 92.5% (95% CI 87.7–95.8%). The strength of 
agreement was very good, with a k value of 0.81 (95% CI 
0.71–0.90).
Analysis of the disagreement
Data reported in Table 2 show an increase of the overall 
agreement between mRNA expression (qRT-PCR) and 
both FISH and Q-PCR when the 22 equivocal cases are 
excluded from the analysis (95.4 vs. 90.8% for the com-
parison with FISH, and 94.7 vs. 90.2% for the comparison 
with Q-PCR). No such improvement is observed when 
the agreement between Q-PCR and FISH is assessed with 
or without the equivocal cases categorized as negative. 
We therefore tested the hypothesis that q-RT-PCR may 
actually recapitulate better HER2 protein overexpression 
than FISH in equivocal cases, by measuring HER2 pro-
tein levels in representative tumor samples.
In particular, we measured HER2 protein levels in 
six equivocal cases and in two remarkable HER2 non-
amplified, mRNA overexpressing cases. Table  3 shows 
the results of Western blot analysis in which the amount 
of HER2 protein is normalized to the structural protein 
γ-tubulin. HER2 protein levels were low or undetect-
able (“negative” blots) in both the HER2-MCF10 control 
cell line and in three negative control patients, and high 
in both the HER2 positive SKBR3 cell line and in one 
positive control patient as assessed by FISH, Q-PCR and 
qRT-PCR (“positive blots”). Protein quantitation was in 
complete agreement with HER2 mRNA in the six FISH 
equivocal cases and in the two cases with mRNA overex-
pression with no evidence of amplification.
Fig. 2 Dilution effect by not-HER2 amplified cells was analyzed in 
serial dilutions of HER2-positive SKBR3 cell line with HER2-negative 
MCF10A cell line. Columns represent the mean of three independent 
experiment performed by Q-PCR (a) and qRT-PCR (b). Copy number 
and gene expression were measured according to the  2−[ΔΔCt] algo-
rithm. SKBR3 is a mammary carcinoma cell line with a medium–high 
level of HER2 amplification. HER2 human epidermal growth factor 
receptor 2, Q-PCR quantitative polymerase-chain-reaction, qRT-PCR 
quantitative reverse transcriptase polymerase-chain-reaction
Table 2 Overall agreement in patient subgroups: all cases versus not equivocal only
CI confidence interval, FISH fluorescence in situ hybridization, DNA deoxyribonucleic acid, mRNA messenger ribonucleic acid
Comparisons Overall agreement (95% CI)
All cases (153) Non equivocal only (124)
FISH vs DNA copy number 94.10 (89.10–97.30) 97.58 (93.13–99.17)
FISH vs mRNA expression 90.80 (85.70–94.90) 95.40 (94.31–99.56)
DNA copy number vs mRNA expression 90.20 (84.46–93.97) 94.70 (90.91–98.27)
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Discussion
Molecular tests for HER2 status determination at DNA 
or RNA level have been widely studied for their potential 
advantages over FISH.
FISH and IHC can be time-consuming, expensive, and 
cumbersome for screening multiple samples over a short 
time. Moreover, these methods are difficult to standard-
ize across laboratories [11, 23].
PCR-based methods may potentially improve the sim-
plicity or accuracy of HER2 testing and have several 
advantages over current methods; they are quantitative 
by definition, do not require extensive training for their 
interpretation, they are not subject to interobserver 
variability, and can be standardized, automated and per-
formed on small samples [24, 25].
Data from published studies comparing these different 
analytical methods are conflicting. At least nine publica-
tions compared DNA copy number measured by PCR 
with in  situ methods, IHC/FISH-CISH. In the past dif-
ferent authors reported an insufficient concordance level 
[26–32] between Q-PCR and IHC/FISH or a clinically 
unacceptable high false negative rate [33], whereas other 
studies showed complete concordance [34, 35]. Particu-
larly, a recent large study performed by Koudelova et al. 
showed that Q-PCR method reached a highly sensitive 
and specificity on the basis of comparison with FISH 
data (94.2 and 100%, respectively) and IHC data (95.1 and 
99.1%). Furthermore the overall concordance of the FISH 
and Q-PCR results is 97.6% [36]. Our experience is in line 
with the observation of a high specificity at a cost of a 
slightly lower sensitivity of Q-PCR over FISH for HER2 
status determination.
Several studies have also compared qRT-PCR based 
gene expression assessment with IHC/FISH. Two of 
them suggested a good agreement between FISH or IHC 
and gene expression analysis performed by real-time 
PCR method, but they were conducted on small patient 
series [37, 38]. Eight studies evaluating the ability of gene 
expression analysis to correctly reproduce HER2 status 
either gave insufficient concordance levels or were una-
ble to evaluate agreement between techniques [28, 32, 
39–44].
Two recent large studies evaluated the concordance 
between the qRT-PCR assessment of HER2 transcript in 
the Oncotype DX assay and FISH [45, 46], and an addi-
tional study compared qRT-PCR and IHC [47]. These 
studies reported high concordance rates between the 
tests, but concluded that the concordance rate was insuf-
ficient to support the use of molecular tests instead of 
in situ methods, in particular when equivocal cases were 
included in the analysis [12].
In a recent work Noske et al. [48] observed, in a cohort 
of 278 patients from the GeparTrio trial, a highly signifi-
cant correlation and a high overall agreement between 
IHC, supplemented by SISH for equivocal cases, and 
qRT-PCR in determining HER2 status. These authors 
also observed a significant discordance between central-
ized and local HER2 determination, hence suggesting the 
importance of reference laboratories for these analyses. 
In contrast with these authors Viale et al. in their analy-
sis of HER2 determination by TargetPrint in the first 800 
patients enrolled in the Mindact Trial, did not find a sig-
nificant difference between centralized and local HER2 
determination. The range of discordance was 0–4.3% for 
Table 3 Analysis of HER2 protein levels in a patient subset
HER2 human epidermal growth factor receptor 2, IHC immunohistochemistry, FISH fluorescence in situ hybridization, mRNA messenger ribonucleic acid, neg negative, 
pos positive
Patient or control IHC FISH Copy number mRNA Protein expression
MCF10 Neg Neg Neg Neg Neg
SKBR3 Pos Pos Pos Pos Pos
p1 Neg Neg Neg Neg Neg
p2 Neg Neg Neg Neg Neg
p3 Equivocal (2+) Neg Neg Neg Neg
p4 Pos Pos Pos Pos Pos
p5 Equivocal (2+) Equivocal Neg Neg Neg
p6 Equivocal (2+) Equivocal Neg Neg Neg
p7 Equivocal (2+) Equivocal Neg Neg Neg
p8 Neg Equivocal Neg Pos Pos
p9 Equivocal (2+) Equivocal Neg Pos Pos
p10 Equivocal (2+) Equivocal Neg Pos Pos
p11 Equivocal (2+) Neg Neg Pos Pos
p12 Equivocal (2+) Neg Neg Pos Pos
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HER2 in six centers [49], likely reflecting a better training 
of the pathologists taking part to the trial.
Furthermore, in the last years, the College of Ameri-
can Pathologists (CAP) has undertaken comprehensive 
efforts to educate pathologists about ways to improve 
laboratory performance of HER2, ER, and PgR assays [1].
The critical point of this quite vast literature is that it 
does not consistently show a sufficient level of agreement 
between molecular and tissue-based tests in defining 
HER2 status, when judged according to ASCO/ACP cri-
teria. Consequently, the use of PCR-based tests in place 
of conventional in  situ methods is not recommended 
[12].
Technical limitations accounting for part of the dis-
crepancies of molecular tests can be circumvented by 
a proper methodological standardization. The puta-
tive dilution or amplification effects are theoretically 
more severe because they pertain to the nature itself of 
molecular tests. In fact, these tests may potentially lead 
to false negative results, especially when a high level of 
intra-tumor heterogeneity accompanies gene amplifi-
cation. The results of our reconstitution in vitro experi-
ments do not support this supposed technical flaw. Both 
Q-PCR and qRT-PCR tests were able to detect the HER2 
increased signal over in a wide range of amplified vs. not 
amplified cells ratios, with fractions of amplified cells as 
small as 5%. However, we are also aware that HER2 copy 
number change in the cell lines tested would have led us 
to different threshold values in our reconstitution experi-
ments. For example, the sensitivity of the method would 
have been lower, if a low-level HER2 amplified cell line 
had been used in place of SKBR3. It is therefore our opin-
ion that the current uncertainties concerning PCR-based 
methods are more due to lack of standardization than to 
an intrinsic limitation.
In our experience, three major points have to be sat-
isfied for the standardization of molecular methods: (i) 
the supervision of sample selection by an experienced 
pathologist, to assure that a suitable amount of infiltrat-
ing tumor cells is analyzed and that in  situ carcinoma, 
potentially overexpressing HER2 [50, 51], is not included 
in the specimen; (ii) a strict control of the quantity and 
quality of DNA/RNA extracted; (iii) the use of extensively 
validated PCR analysis algorithms to measure the DNA/
RNA templates in the tumor samples [19].
In this study, the results obtained on the overall patient 
population show a high overall concordance (94.1%) in 
HER2 copy number, as determined by Q-PCR and FISH. 
Assuming FISH as the reference standard, the sensitiv-
ity and specificity of Q-PCR are 86 and 99%, respectively, 
with a global accuracy of 98%. These data support the 
possibility to use Q-PCR, as carried out in this study, as 
an acceptable alternative for FISH.
On the other hand, the comparison of HER2 mRNA 
expression, as determined by qRT-PCR, with FISH 
results gives an overall concordance of 90.8%, insufficient 
to warrant the use of gene expression analysis in place of 
FISH, according to 2013 ASCO/CAP criteria and to our 
pre-specified criteria [1].
Viale et al. in a recent large study confirm that the posi-
tive agreement for TargetPrint, a microarray analysis to 
determine HER2 with IHC/FISH is comparable with 
other mRNA readouts, implying that gene expression 
and DNA evaluation of HER2 may not be interchange-
able [49].
Nonetheless, the comparison of results from the 
total population with those from the subgroup of non-
equivocal cases only (Table  2) clearly shows that the 
disagreement between qRT-PCR and FISH or Q-PCR 
is essentially limited to equivocal cases, as defined by 
ASCO/CAP criteria for FISH assessment of HER2 status.
In fact, one-third of these patients, considered HER2− 
by both FISH and Q-PCR, shows some degree of HER2 
mRNA overexpression by qRT-PCR analysis compared 
to negative controls. These discordant cases are more 
prevalent in the equivocal subgroup, in which HER2 
copy number has a relatively small range of variation. A 
putative high false-positive rate of the qRT-PCR test in 
this range of values may offer an easy explanation for 
the observed results. However, previous analyses on fro-
zen breast cancer samples made by solid matrix blotting 
techniques unequivocally demonstrated that gene ampli-
fication is closely associated with protein overexpression 
[7]. Consequently, HER2 protein direct measurement can 
be well considered as the true standard control for all the 
other surrogate methods for HER2 characterization [4].
We therefore hypothesized that the high accuracy of 
qRT-PCR compared to the other methods for HER2 sta-
tus evaluation could account for the discordant results we 
observed. Accordingly, we set up a control experiment by 
directly measuring HER2 protein levels in a representa-
tive subgroup of cases (Table 3).
The analysis conducted directly on this case set shows a 
strong correlation between mRNA and protein levels. In 
particular, high HER2 protein levels were found in qRT-
PCR positive, IHC/FISH equivocal cases, but not in those 
lacking mRNA overexpression. These results suggest that 
qRT-PCR may indeed be a better proxy for determin-
ing HER2 protein levels than FISH. Moreover, qRT-PCR 
may be of greater use than FISH in those cases with low 
level of HER2 amplification, when in  situ analysis can 
miss its surrogate endpoint of identifying HER2 positive 
cases. Hence, as for Q-PCR, qRT-PCR may find its role 
in the subpopulation of patients for whom a reflex test 
is required after FISH yields equivocal results, or where 
the starting material is too exiguous for definitive FISH 
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assessment (e.g., in fine needle aspiration biopsies, as 
we showed in a previous publication [52]). It is presently 
unclear which of the two molecular methods should be 
preferred.
Indeed, in light of the above considerations, qRT-PCR 
also outperforms Q-PCR in specific settings, our conclu-
sion apparently contradicts the results of in  vitro serial 
dilution experiments showing an equal detection thresh-
old of the two molecular tests. However, it should be 
noted that these experiments were designed to address 
the question of the dilution effect, and not to determine 
the minimal amount of HER2 DNA or RNA molecules 
respectively detectable by the two PCR-based assays.
High levels of HER2 protein were also found in the two 
non-equivocal cases with mRNA overexpression without 
amplification according to both FISH and copy number 
analysis. Cases like these could represent a true altera-
tion of gene expression control or alternatively a very low 
level of amplification [2, 53]. The most relevant point in 
such cases is that they reinforce the notion of the supe-
rior accuracy of qRT-PCR compared to other methods to 
define HER2 status. However, we feel the need to caution 
the Reader about the possible over-interpretation of our 
results, in that the case set for which we could perform 
the combined assessment of DNA copy number by both 
FISH and Q-PCR, RNA abundance, and protein lev-
els is relatively small, hence the results deriving from its 
analysis are to be considered as exploratory and hypoth-
esis-generating rather than conclusive. Another relevant 
point to be taken into consideration is that in our series, 
the optimal cut-off for defining the results of q-RT-PCR 
as positive was obtained by fitting a model. Were this 
method to be diffused amongst laboratories, a universal 
calibration reference should be used (e.g., cDNA from a 
known and well-studied breast cancer HER2-amplified 
cell line mixed at serial dilutions with donors’ cDNA, 
with the caveat of using the same batch of cancer cell 
lines from a commercial vendor due to the risk of copy 
number drift over time for cell cultures kept in individual 
laboratories). A promising solution to such non-trivial 
limitation would be the adoption of digital PCR, which 
does not require normalization with reference tran-
scripts. Reports in this regard have been recently pub-
lished [54–56], and prospective studies should aim to 
assess the role of such novel and potentially more accu-
rate methods in the landscape of HER2 status determina-
tion technologies.
While not meaning to be exhaustive (which would 
be outside the scope of the present article), we wish to 
observe that the costs of PCR methods are, in general, 
extremely affordable: the acquisition of a good thermo-
cycler in the European Community is in the order of few 
tens of thousand euros for top brands, and the actual cost 
(with the reagents described in the “Methods”) of a PCR 
performed in technical triplicate is around 30 Euro (33 
US $ at the current conversion rate). Moreover, the per-
son-time with the help of automated nucleic acid extrac-
tion devices is relatively contained, generally less than 
1 h and a half of hands-on time and data analysis. These 
layman considerations should be taken into account for 
possible practical uses of PCR in HER2 determination 
in real-life practice and in the proper context (i.e., when 
skilled personnel is available).
Grant et al. supported the use of microarray analysis by 
TargetPrint to determine HER2 status in breast cancer. 
This study found a 100% concordance rate between IHC/
FISH and TargetPrint results for HER2 tumour status 
and, furthermore, added important informations in all 
equivocal cases of study. HER2 positive status assigned 
by TargetPrint in those patients with an equivocal ISH 
result facilitated treatment decision-making based on a 
binary value, which excluded the previous uncertainty of 
indeterminate ISH reporting [57].
From a clinical point of view, patients with HER2 tran-
script and protein overexpression, with a negative FISH 
result, are considered HER2− according to standard 
criteria, and consequently they are not eligible for anti-
HER2 therapies.
In our series these cases were around 8%, although 
this value is not representative of the entire breast can-
cer population, because we deliberately enriched our 
sample set in equivocal cases. These cases are likely to 
be more rarely observed in daily practice, albeit, extrap-
olating from our study and from breast cancer epidemi-
ology, they may represent a small but clinically relevant 
breast cancer population not benefitting from anti-HER2 
treatments.
These cases we characterized might well correspond 
to the small breast cancer patients subset considered 
as HER2-tumors but, nonetheless, responding to tras-
tuzumab in both adjuvant and metastatic settings [7, 8, 
10]. Breast cancer samples overexpressing HER2 in the 
absence of gene amplification can also be found in the 
METABRIC project dataset [58]. The cause of HER2 non-
amplification-driven overexpression in this small breast 
cancer subset is unclear, although aberrant regulation by 
miRNAs [59, 60] may play a role in this context.
Conclusion
While pre-analytical limitations can affect both PCR 
and FISH, IHC and, especially, ISH analysis are prone 
to subjective evaluation even by skilled operators: our 
work suggests that qRT-PCR could be proposed as a 
more objective test, especially in FISH equivocal cases. 
Potential applications include the use of qRT-PCR as a 
second level reflex test after FISH, and the determination 
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of HER2 status when analytical material is too little for 
obtaining an accurate result, such as in certain fine nee-
dle aspiration biopsies.
From a biological perspective, the results of our qRT-
PCR analyses provide the proof of principle that this 
technique may be as accurate as FISH or even more in 
certain contexts to identify patients with HER2 protein 
increased abundance.
Furthermore, our analyses support the use of qRT-
PCR for HER2 mRNA expression as a second level test to 
define HER2 status in FISH equivocal cases, in order to 
administer potentially effective anti-HER2 treatments in 
this small but non-negligible subset of patients.
In the future, PCR methods should achieve a greater 
standardization, and being faster and cheaper than 
other methods to detect HER2 on DNA and RNA levels, 
they could be useful adjuncts of IHC/FISH. Prospective 
assessments in larger patient populations are needed for 
a more exhaustive resolution of this relevant issue.
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